- Home
- ORIQ vs ICCC Comparison
ORIQ vs ICCC Comparison
Compare ORIQ & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORIQ | ICCC |
|---|---|---|
| Founded | 2024 | 1982 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.2M | 93.1M |
| IPO Year | 2025 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ORIQ | ICCC |
|---|---|---|
| Price | $10.45 | $10.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 45.4K | 7.4K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $25.34 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $10.10 | $4.52 |
| 52 Week High | $10.45 | $12.10 |
Technical Indicators
Market Signals| Indicator | ORIQ | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 51.34 |
| Support Level | $10.34 | $9.45 |
| Resistance Level | $10.45 | $10.82 |
| Average True Range (ATR) | 0.00 | 0.23 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 99.75 | 50.58 |
Price Performance
Historical ComparisonAbout ORIQ Origin Investment Corp I Ordinary Shares
Origin Investment Corp I is a blank check company.
About ICCC ImmuCell Corporation
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.